title: [Pre-exposure prophylaxis for HIV transmission? No, unless].
abstract: Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) will soon be available in the Netherlands. Moderate evidence concerning practical efficacy, small absolute risk reduction (1-2%) and a high number needed to treat (50-75) are key figures. Prevention of one HIV infection will cost EUR 350,000 to 500,000. No information is available on long-term renal function and antiretroviral resistance. Guidelines are needed before treatment with PrEP is introduced in the Netherlands.
authors.affiliation: Huisartsenpraktijk Postjesweg, Amsterdam, the Netherlands. ajpboeke@wxs.nl
authors.forename: A J P Joan
authors.initials: AJ
authors.lastname: Boeke
authors.forename: Adrie M
authors.initials: AM
authors.lastname: Heijnen
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018890:Chemoprevention; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000068679:Emtricitabine; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage*; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine